U.S. market Closed. Opens in 2 hours 10 minutes

APDN | Applied DNA Sciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.1600 - 0.1675
52 Week Range 0.1500 - 22.80
Beta 1.01
Implied Volatility 523.63%
IV Rank 100.00%
Day's Volume 1,620,331
Average Volume 6,895,370
Shares Outstanding 50,480,500
Market Cap 8,329,283
Sector Healthcare
Industry Medical - Diagnostics & Research
IPO Date 2003-07-15
Valuation
Profitability
Growth
Health
P/E Ratio -0.02
Forward P/E Ratio N/A
EPS -7.50
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 52
Country USA
Website APDN
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
APDN's peers: BDSX, DRIO, OLK, GTH, XGN, BNR, STIM, SERA, OCX, PSNL, IDXG, ISPC, TRIB, MYNZ, PRE, FONR, PRPO
*Chart delayed
Analyzing fundamentals for APDN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see APDN Fundamentals page.

Watching at APDN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on APDN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙